Skip to content
Sudarshan Pharma Industries logo

Sudarshan Pharma Industries

SUDARSHAN NSE
₹32.20 No trade today
P/E
31.26
View as Markdown
MCP
Close 4 Nov 2026 ₹32.20 +4.02 +14.3% 1Y
Start ₹28.18

Key Fundamentals

MicrocapSpecialty ChemicalsChemicals

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
15.10%
Debt to Equity
1.84
EPS (TTM)
₹1.03
Book Value
₹7.68
Market Cap
—
P/E (TTM)
31.26
P/B
4.19
ROE
16.30%
Dividend Yield
0.93%
EBITDA
₹60.00 Cr
52W High
₹42.79
52W Low
₹18.50
Volume
0

Peer Comparison

Commodities › Chemicals › Dyes & Pigments › Specialty Chemicals

Sudarshan Pharma Industries peer comparison
Pidilite Industries
₹1,510.2058.04₹1,54,107 Cr13.721.42%23.90%31.00%₹15,399 Cr₹2,677 Cr
Gujarat Fluorochemicals
₹4,613.3083.76₹49,073 Cr6.040.07%7.82%9.64%₹5,303 Cr₹600 Cr
Navin Fluorine International
₹8,785.0057.03₹44,060 Cr10.100.09%19.60%21.00%₹3,634 Cr₹789 Cr
Deepak Nitrite
₹1,578.4027.48₹20,919 Cr3.320.49%9.82%11.40%₹8,575 Cr₹784 Cr
Aether Industries
₹1,540.7086.90₹20,030 Cr7.880.00%9.66%11.90%₹1,231 Cr₹235 Cr
Aarti Industries
₹447.5530.57₹15,838 Cr2.590.23%7.13%6.86%₹9,010 Cr₹531 Cr
Atul
₹5,156.5019.67₹14,827 Cr2.310.59%11.50%14.90%₹6,969 Cr₹788 Cr
Sudarshan Pharma Industries (this company)
₹32.2031.26₹810 Cr4.190.93%16.30%15.10%₹732 Cr₹25 Cr
Median 8 companies₹1,559.5544.15₹20,474 Cr5.120.36%10.66%13.40%₹6,136 Cr₹692 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

45 Average

Data confidence 100/100

Category scores

Quality
37
Poor
Returns, margins, earnings quality 22% weight
Valuation
28
Poor
Cheap vs sector & own history 24% weight
Growth
91
Strong
Sales & profit trajectory 9% weight
Financial Health
25
Poor
Solvency, leverage, coverage 9% weight
Momentum
43
Weak
Trend strength, vol-adjusted 12% weight
Ownership
62
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 54.2% CAGR over last 5 years
  • Promoter holding has increased by 1.54% over last quarter.
  • Company's working capital requirements have reduced from 43.9 days to 17.1 days

Weaknesses

2
  • Stock is trading at 5.65 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1261
OscillatorsBearish261
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
38.68
Neutral
MACD (12,26,9)
−1.07
Bearish
SMA (50)
37.70
Bearish
SMA (200)
32.69
Bearish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+29.50%
3Y+15.10%
1Y+39.21%
TTM+32.87%

Net profit

Net profit growth by window
5Y+50.29%
3Y+48.67%
1Y+43.75%
TTM+24.34%

Operating cash flow

Operating cash flow growth by window
5YTurned negative
3YOutflow narrowed by ₹27 Cr
1YOutflow narrowed by ₹30 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+3.62 pp
3Y+4.00 pp
1Y−0.67 pp
TTM−1.04 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹148 Cr
Mar 2021₹193 Cr
Mar 2022₹357 Cr
Mar 2023₹461 Cr
Mar 2024₹464 Cr
Mar 2025₹505 Cr
Mar 2026₹703 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020₹1.00 Cr
Mar 2021₹3.00 Cr
Mar 2022₹5.00 Cr
Mar 2023₹7.00 Cr
Mar 2024₹11.00 Cr
Mar 2025₹16.00 Cr
Mar 2026₹23.00 Cr

Quarterly Results

₹ Cr
543828 quarterly results, ₹ crore
Particulars Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
99.2
129
116
162
145
169
168
221
174
217
Expenses
97.12
116
108
146
134
160
157
201
159
196
Operating Profit
2.08
13.05
7.97
15.93
11.04
9.21
10.87
20.2
15.9
20.58
OPM %
2.1%
10.15%
6.89%
9.86%
7.6%
5.45%
6.47%
9.14%
9.12%
9.49%
Other Income
0.98
−0.85
0.51
−0.81
1.21
1.86
1.52
4.13
1.22
1.93
Interest
3.94
3.7
4
4.4
5.96
5.94
6.28
7.53
8.21
10.36
Depreciation
0.67
0.67
0.63
0.83
0.88
0.9
0.91
1.09
1.41
1.36
PBT
−1.55
7.83
3.85
9.89
5.41
4.23
5.2
15.71
7.5
10.8
Tax %
−21.94%
24.9%
24.94%
25.08%
26.8%
8.51%
20.19%
27.43%
25.33%
27.96%
Net Profit
−1.21
5.88
2.88
7.41
3.96
3.87
4.15
11.4
5.61
7.78
EPS (₹)
−0.05
0.24
0.12
0.31
0.17
0.17
0.18
0.45
0.23
—

Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
543828 profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
148
193
357
461
464
505
703
732
Expenses
143
186
346
446
441
465
652
676
Operating Profit
5
7
11
15
23
40
51
56
OPM %
3.2%
3.7%
3.1%
3.2%
4.9%
8%
7%
8%
Other Income
0
0
0
1
3
0
9
9
Interest
3
3
3
5
9
16
26
28
Depreciation
0
1
1
1
1
2
4
4
PBT
2
4
7
9
15
22
31
33
Tax %
26%
25%
26%
26%
25%
26%
23%
—
Net Profit
1
3
5
7
11
16
23
25
EPS (₹)
0.09
0.19
0.36
0.29
0.48
0.66
0.97
1.03
Div. Payout %
0%
0%
0%
10%
0%
0%
0%
—

Balance Sheet

₹ Cr
543828 balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
10
10
10
24
24
24
24
Reserves
10
13
20
77
88
107
131
Borrowings
21
30
31
34
105
171
285
Other Liabilities
18
47
77
97
67
100
202
Total Liabilities
58
99
138
232
283
402
642
Fixed Assets
6
6
6
20
26
48
104
CWIP
0
0
1
0
2
23
3
Investments
0
0
0
12
14
30
0
Other Assets
53
93
131
200
242
302
534
Total Assets
58
99
138
232
283
402
642

Cash Flow

₹ Cr
543828 cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1
3
−4
−29
6
−32
−2
Investing
−3
−1
−1
−26
−5
−21
−78
Financing
0
−1
4
66
−12
53
79
Net Cash Flow
−2
0
−1
11
−12
0
−1
Free Cash Flow
−4
1
−5
−43
2
−54
−51
CFO/EBITDA
20
50
−19
−179
36
−74
7

Ratios

543828 financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
66
114
75
64
96
116
121
Inventory Days
46
49
51
63
74
117
129
Days Payable
40
91
80
78
49
76
111
Cash Conversion Cycle
72
72
46
50
122
156
139
Working Capital Days
35
29
27
54
62
52
17
ROCE %
—
15%
19%
15%
14%
16%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sudarshan Pharma Industries insights

62 extracted metrics across FY16–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 57.81%
  • FIIs 21.95%
  • Public 16.58%
  • Others 3.61%
  • Government 0.05%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

  • Concall · Aug 2026
    PPT
  • Concall · Aug 2026
    PPT
  • Concall · May 2026
    PPT
  • Concall · Jan 2026
    PPT
  • Concall · Aug 2025
    PPT

Frequently Asked Questions about Sudarshan Pharma Industries

What does Sudarshan Pharma Industries Ltd do?
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents
Where is Sudarshan Pharma Industries Ltd (SUDARSHAN) listed?
Sudarshan Pharma Industries Ltd trades as SUDARSHAN on the NSE and under code 543828 on the BSE.
Which sector does Sudarshan Pharma Industries Ltd belong to?
Sudarshan Pharma Industries Ltd is classified under the Chemicals sector, in the Dyes & Pigments industry.
What is the PE ratio of Sudarshan Pharma Industries Ltd?
Sudarshan Pharma Industries Ltd trades at a PE ratio of 31.26 as of 4 Nov 2026, on earnings per share of ₹1.03, against a book value of ₹7.68 per share.
What is the 52-week high and low of Sudarshan Pharma Industries Ltd?
Over the last 52 weeks Sudarshan Pharma Industries Ltd has traded between ₹18.5 and ₹42.79 as of 4 Nov 2026.
Does Sudarshan Pharma Industries Ltd pay dividends?
Sudarshan Pharma Industries Ltd has a dividend yield of 0.93%.
What is the Return on Equity (ROE) of Sudarshan Pharma Industries Ltd?
Sudarshan Pharma Industries Ltd reported a return on equity of 16.30%. Its debt-to-equity ratio is 1.84.

Company Information

Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents

Website sudarshanpharma.com
Listed 22 Mar 2023
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543828.md for Sudarshan Pharma Industries Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Chemical & Petrochemical stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month